This prospective cohort study aimed to investigate the association of NAFLD and liver enzymes (AST, ALT, ALK-P, and GGT) with the incidence of CVD in patients with T2D in a median of 5-year follow-up [22, 23]. This evidence concerns the gene ALK and metabolic dysfunction-associated steatotic liver disease.